An international multi-centre long term follow up study of the long term outcomes and impact of cancer treatments in 'triple negative' breast cancer

Trial Profile

An international multi-centre long term follow up study of the long term outcomes and impact of cancer treatments in 'triple negative' breast cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Anthracyclines; Taxanes
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms LOTUS
  • Most Recent Events

    • 17 Dec 2015 Accrual to date is 53% according to the United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to date is 44% according to the United Kingdom Clinical Research Network record.
    • 05 Oct 2015 Accrual to date is 36% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top